These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16737009)

  • 41. Health care technology, inflation, and outcomes: take heart.
    Reece RL
    Minn Med; 1989 Jun; 72(6):323, 325. PubMed ID: 2739634
    [No Abstract]   [Full Text] [Related]  

  • 42. A randomized trial of stenting with or without balloon predilation for the treatment of coronary artery disease.
    Kovar LI; Monrad ES; Sherman W; Kunchithapatham S; Ravi KL; Gotsis W; Silverman G; Brown DL
    Am Heart J; 2001 Nov; 142(5):E9. PubMed ID: 11685184
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SCAI statement on ad hoc versus the separate performance of diagnostic cardiac catheterization and coronary intervention.
    Blankenship JC; Klein LW; Laskey WK; Krone RJ; Dehmer GJ; Chambers C; Cowley M
    Catheter Cardiovasc Interv; 2004 Dec; 63(4):444-51. PubMed ID: 15558758
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improving efficacy, efficiency and economics of hospice individualized drug therapy.
    Lycan J; Grauer P; Mihalyo M; Houchen B
    Am J Hosp Palliat Care; 2002; 19(2):135-8. PubMed ID: 11926445
    [No Abstract]   [Full Text] [Related]  

  • 45. [Conference on pharmacoeconomics and quality of life in dermatology--outcomes research in the clinic and in research. March 20-21,1998 in Freiburg, Bavaria].
    Klyscz T
    Hautarzt; 1999 Jun; 50(6):446-7. PubMed ID: 10427516
    [No Abstract]   [Full Text] [Related]  

  • 46. Drug costs and treatment choices: a DTB symposium.
    Drug Ther Bull; 1993 May; 31(11):41-4. PubMed ID: 8344136
    [No Abstract]   [Full Text] [Related]  

  • 47. From Science to Finance-A Tool for Deriving Economic Implications from the Results of Dietary Supplement Clinical Studies.
    Shanahan CJ; de Lorimier R
    J Diet Suppl; 2016; 13(1):16-34. PubMed ID: 25166888
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Economic issues in coronary heart disease prevention in India.
    Gupta R; Prakash H; Gupta RR
    J Hum Hypertens; 2005 Aug; 19(8):655-7. PubMed ID: 15829996
    [No Abstract]   [Full Text] [Related]  

  • 49. Angioplasty--hospital costs, 1986.
    Stat Bull Metrop Insur Co; 1989; 70(3):11-7. PubMed ID: 2527417
    [No Abstract]   [Full Text] [Related]  

  • 50. Medical economic considerations of coronary stenting.
    Szucs TD
    Schweiz Med Wochenschr; 1999 Nov; 129(45):1701-11. PubMed ID: 10595380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and economic implications of new strategies for heart failure management in the managed care setting.
    Chase SL; Pickworth KK
    Pharmacotherapy; 2007 Apr; 27(4 Pt 2):29S-32S. PubMed ID: 17381372
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacoeconomics: therapeutic and economic considerations in treating the critically ill patient.
    Crane VS
    DICP; 1990 Nov; 24(11 Suppl):S24-7. PubMed ID: 2125394
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluating the costs and benefits of using combination therapies.
    Rodgers A; Laba TL; Jan S
    Med J Aust; 2014 Oct; 201(8):447-8. PubMed ID: 25332026
    [No Abstract]   [Full Text] [Related]  

  • 54. New trends in cardiovascular therapy and technology. 19-22 June 1991, Genoa, Italy. Proceedings.
    Eur Heart J; 1991 Dec; 12 Suppl G():1-57. PubMed ID: 1806372
    [No Abstract]   [Full Text] [Related]  

  • 55. PRESENT TRENDS IN CORONARY DISEASE.
    REDLEAF PD
    J Lancet; 1965 Jul; 85():279-82. PubMed ID: 14341762
    [No Abstract]   [Full Text] [Related]  

  • 56. Light at the end of the tunnel?: The Great Indian Pharmacoeconomics story.
    Thakkar KB; Billa G
    Front Pharmacol; 2013; 4():153. PubMed ID: 24379781
    [No Abstract]   [Full Text] [Related]  

  • 57. Drug policy research & pharmacoeconomics.
    Indian J Pharmacol; 2008 Oct; 40(Suppl 2):S176-8. PubMed ID: 21593973
    [No Abstract]   [Full Text] [Related]  

  • 58. Future Prospects for Pharmacoeconomics and Outcomes Research in the Emerging Regions.
    Drummond M
    Value Health Reg Issues; 2013 May; 2(1):3-4. PubMed ID: 29702849
    [No Abstract]   [Full Text] [Related]  

  • 59. Grand challenges in pharmacoeconomics and health outcomes.
    Dubois DJ
    Front Pharmacol; 2010; 1():7. PubMed ID: 21713104
    [No Abstract]   [Full Text] [Related]  

  • 60. The signal strengthening power of statistics: a demonstration of regression with unknown model domain in statistics and pharmacoeconomics.
    Neumann K
    Pharmacoepidemiol Drug Saf; 1997 Oct; 6 Suppl 3():S27-9. PubMed ID: 15073751
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.